Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Chenodeoxycholic Acid Capsules in Healthy Subjects
NCT06180057Phase 1Completed
- Sponsor
- Humanis
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of chenodeoxycholic acid in cerebrotendinous xanthomatosis (CTX) (2 arms), sponsored by Humanis. Primary endpoints: Maximum observed plasma concentration at 72 hours and Area under the plasma concentration-time curve from time 0 to 12 hours. Started Jun 2022; status: completed.
02
Drugs
chenodeoxycholic acid
03
Conditions
cerebrotendinous xanthomatosis (CTX)
Beyond the preview
Go deeper on NCT06180057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180057.